Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: Directors Deals Ltd.
$12.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Recipharm announces exercise of over-allotment option in relation to shares of series B


Friday, 11 Apr 2014 01:30am EDT 

Recipharm publ AB:Says, in connection with its IPO, Carnegie Investment Bank AB (publ) and SkandinaviskaEnskildaBanken AB (publ) have exercised the over-allotment option in full in respect of 2,517,884 existing shares of series B in Recipharm.Following the exercise of the over-allotment option, the main owners Lars Backsell and Thomas Eldered, will hold 16,578,123 shares in Recipharm, corresponding to about 45 pct of the shares and about 86 pct of the votes in the company.Lars Backsell and Thomas Eldered acted through the company B&E Participation AB.The banks have also notified Recipharm that the stabilization period in respect of the offer has ended on April 11 and confirmed that there have not been any stabilization transactions in respect of the offer. 

Company Quote

182.0
3.5 +1.96%
27 Feb 2015